OxyContin Patent Claims Invalid

Purdue Pharma L.P. et al. v. Teva Pharmaceuticals, USA, Inc.

Case Number: 1:12-cv-05083-SHS (Dkt. 46)

In light of the court’s Findings of Fact and Conclusions of Law (Dkt. 149), Judge Stein entered the following declaratory judgments:

  • Claims 3 and 19 of U.S. Patent No. 7,674,799 (entitled “Oxycodone hydrochloride having less than 25 ppm 14–hydroxycodeinone”) are invalid
  • Claims 30–34 and 76–79 of U.S. Patent No. 7,674,800 (same) are invalid
  • Claims 1, 4, and 5 of U.S. Patent No. 7,683,072 (same) are invalid
  • Teva’s proposed products do not infringe claims 1, 2, 6, and 9 of U.S. Patent No. 7,776,314 (entitled “Abuse-proofed dosage form”)
  • Claims 1, 2, 5, 7, and 8 of U.S. Patent No. 8,114,383 (same) are invalid.

Judge Stein said that Teva had not shown that the case was exceptional, and so declined to award attorney fees.

The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.